塩酸ブナゾシン（選択的α1遮断剤）点眼のヒト眼圧に対する効果

Hypotensive effect of topical bunazosin hydrochloride, a selective alpha-1 blocker, in human eyes

　新しいα₁遮断剤である塩酸ブナゾシン点眼液が，健常者や高眼圧症患者の眼圧などに及ぼす影響を検討した。健常者では0.025〜0.2％液の1回点眼により，処置眼で初期値または対照眼に対して有意な眼圧下降を示し，最大の下降は5〜7時間後に認めた。0.1％液が最人の下降作用（初期値に比べ−3.8±0.9mmHg）を示した。0.1％液でやや縮瞳傾向を認めたが，0.05％以下の液では縮瞳傾向を認めなかった。前房深度，近点距離，血圧，脈拍数には有意な変化がなかった。0.2％液では刺激感や眼重感を生じたが，0.1％以下の液では軽度の結膜充血以外，副作用を生じなかった。0.1％液の1週間連続点眼（1日2回）の忍容性は良好で，7日目にも点眼による有意な眼圧下降を認めた。高眼圧症患者では低濃度液（0.005％，0.01％）にて有意な眼圧下降を認め，結膜充血は軽減された。以上の結果から，塩酸ブナゾシン点眼液の緑内障への臨床応用が期待される。

We evaluated the effect of topical instillation of bunazosin hydrochloride, a new alpha -1 adrener-gic antagonist, on the intraocular pressure (IOP) in 2 patients with ocular hypertension (OH) and 6 normotensive human volunteers (NHV).

Significant reduction in IOP resulted after a single instillation of 0.025%/0.2%bunazosin. The maximum reduction occurred 5 to 7 hours after instillation. Miosis was minimum or absent. There was no signficant change in anterior chamber depth, near point, systemic blood pressure or the pulse rate. Slight conjunctival hyperemia was thesole ocular complication with 0.1%bunazosin. Burn-ing sensation and ocular dullness were claimed with 0.2%solution.

Instillation of 0.1%solution twice daily for one week was well tolerated, topically and systemical-ly, in NHV. A significant reduction in Iop was present throughout the 7-day period.

Significant IOP reduction resulted in OH after instillation of 0.01%and 0.005%solution. The mag-nitude of hypotensive effect of 0.01%solution in OH was comparable to that of 0.1%solution in NHV.

The findings seemed to suggest the clinical use-fulness of topical bunazosin for ocular hypertension and, possibly, for glaucoma.